News 2017-03-17
Porton Completes Move to New Headquarters.
Mar 17, 2017, Chongqing, China: Porton Fine Chemicals is pleased to announce the relocation of its global headquarters and Chongqing Process R&D Center to a state of the art facility located in Shuitu High-Tech Park near Chongqing International Airport, China. Located on a beautiful 20 km2 campus, Porton’s Shuitu Headquarters offers 4,800 m2 of state of the art office and conference space, and hosts all centralized corporate and back-office functions to seamlessly support our sites in China, Europe and the United States.
Porton’s Shuitu campus also features our new state of the art Chongqing Process R&D Center. Featuring 4,800 m2 of R&D space including process laboratories, analytical chemistry zone, kilo-laboratory assets, hydrogenation and process safety laboratories, our Shuitu Process R&D Center brings the collective expertise and experience of >100 process chemists and analytical scientists. We are truly excited about applying this world-class facility’s capabilities to deliver compelling, cross life-cycle chemical process innovation solutions to our valued global pharmaceutical industry customers. Contact us today to attend our Open House on June 25th, 2017 or to schedule a private tour at your convenience.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
